10.02.12
The Frost & Sullivan Product Differentiation Excellence Award has honored Oslo, Norway’s Epax for its condition-specific range of concentrated EPA/DHA omega 3 ingredient products and the company’s success in carving out a niche in a crowded market.
“Product differentiation is one of the prime factors that define success in the omega-3 market,” said Frost & Sullivan research analyst, Ashwin Raj Ravinder. “Epax abides by the strictest norms, right from choosing the raw material to final delivery, and they consistently deliver products with the best purity profile in the industry.”
The Epax product range contains an optimum EPA and DHA ratio that offers a cost-effective solution. Multiple clinical studies and the European Food Safety Authority (EFSA) approved health claims strengthen Epax’s marketability and presence.
Epax also received Frost & Sullivan’s Excellence in Product Quality Award in 2008.
“Product differentiation is one of the prime factors that define success in the omega-3 market,” said Frost & Sullivan research analyst, Ashwin Raj Ravinder. “Epax abides by the strictest norms, right from choosing the raw material to final delivery, and they consistently deliver products with the best purity profile in the industry.”
The Epax product range contains an optimum EPA and DHA ratio that offers a cost-effective solution. Multiple clinical studies and the European Food Safety Authority (EFSA) approved health claims strengthen Epax’s marketability and presence.
Epax also received Frost & Sullivan’s Excellence in Product Quality Award in 2008.